Skip to main
MGX

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. has developed a comprehensive metagenomics-derived genome editing toolbox that facilitates a range of genetic modifications, positioning the company as a significant player in the genetic medicines sector. The company’s pipeline includes promising product candidates targeting serious disorders such as Hemophilia A, which demonstrated durable Factor VIII levels of 80% over a 19-month period in non-human primate studies, indicating potential therapeutic effectiveness. With a strategic focus on vivo gene editing and technology out licensing for ex vivo cell therapy, Metagenomi is well-positioned to leverage its innovative capabilities to capture market opportunities in the evolving field of genetic medicine.

Bears say

Metagenomi Inc. reported a net loss of $19.9 million, or $0.54 per share, for the second quarter of 2025, reflecting ongoing financial challenges as the company invests in its gene editing pipeline. The company is trading significantly below its cash value, which presents potential upside; however, several risks loom, including potential delays in advancing clinical candidates and the inability to generate favorable data from key programs, particularly those targeting Hemophilia A. Additionally, there is a concern regarding possible long-term dilution, which could further impact shareholder value and sentiment toward the stock.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.